Shares of XenoPort were buoyed by the news that regulators had asked for preclinical data on its experimental therapy for restless leg syndrome but were not asking for any new trials. XenoPort plans to file a complete response to the FDA in the second half of the year. "We believe this is an incremental positive for the company as a path toward an approval of Horizant has been identified," said Leerink Swann analyst Steve Yoo. Report
Read the full article at FierceBiotech
